Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

04-Oct-2016 8:00 AM

 

New regional BioPharma Services’ dedicated solution enables seamless support for global cell and gene therapy clinical trials across multiple geographies for biopharmaceutical customers

 
Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials i ...

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan (Photo: Business Wire)


TOKYO--()--To help meet increasing demand for cell and gene therapy clinical trial support around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies. As a leading service provider to the cell and gene therapy community, Fisher BioServices is uniquely positioned with the experience, resources, and global expertise to support its customers on their path towards commercialization.

 

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161003005027/en/

The facility in Tokyo was expanded to include cryogenic storage and logistics by utilizing a combination of proven components and validated procedures developed with years of experience in the cell and gene therapy business. The new modules within this facility allow Fisher BioServices to configure and replicate each site to meet the specific requirements of individual clinical trials with minimal variation, regardless of volume or geographic location. The facility is also supported by a global comprehensive and integrated Quality System based on regulatory requirements, industry best practices and trained personnel.

“Japan is an increasingly important market for cell and gene therapy companies conducting clinical trials,” said Dennis Barger, Fisher BioServices vice president and general manager. “The addition of cryogenic services to this facility in Japan, combined with our existing capabilities in Europe and the US, enables us to seamlessly support our customers’ global trials as they develop and commercialize their therapies.”

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

 

 

Contacts

Thermo Fisher Scientific
Marcia K. Goff, +1-508-902-7041
marcia.goff@thermofisher.com

 

 

 

 

Topic: Science

Media contact

Lauren Taylor
Account Executive Australia and New Zealand

lauren.taylor@businesswire.com

Tel: 02 9004 7015

Tags

About us

With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193 industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built on our patented simultaneous and secure NX network and augmented with partnerships with international and national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and consumers.

More in Business Wire Australia and New Zealand